Every sense I get is that JT is in it for the long haul. He has a chance to revisit his glory years at Amgen where he helped make Neulasta huge. Heck, if he gets a tenth of Neulasta sales ($400M) w Rolontis, that would be a big feather in his cap. They would be an earnings positive biotech not having to worry about money. That along with pozi moving along smoothly to approval and he'll be king of Spectrum till he's 70 or in Raj's case 75;). And unlike Howard Pien of Medx, JT works where everyone else under him at Spectrum works which is on the West Coast. He mentioned at the Noble CC that he was from Florida where the CC was being held and this was an opportunity to visit his Mom.
News 
Market Data 
Discover 
